Investigational and not approved by the FDA. This page is educational information only. It is not medical advice and not a recommendation to use anything.

IndexedBuilt automatically from public databases on 2026-09-30. Not yet hand-reviewed by PLOBT.How this works →

Petrelintide

Investigational

Long-acting amylin analog

Also known as: ZP8396, ZP-8396

Evidence score

58/ 100

Moderate evidence

A real evidence base, with gaps

Regulatory standing. In clinical trials, not yet approved
Limited human data. Some human data exists, not conclusive
Registered human trials. 9 registered studies on ClinicalTrials.gov, most advanced Phase 3
1 cited source. Includes primary / regulatory sources

Computed with the same four public criteria as every profile. The human-evidence grade on an indexed profile is set automatically and may change when it is hand-reviewed. It is not a safety score, not a purity rating, and not medical advice, and not a claim that this compound treats, cures, or prevents any condition.

What it is

Petrelintide, also known as ZP8396, is an investigational synthetic peptide designed to mimic amylin, a hormone released from the pancreas alongside insulin. It is engineered to last longer in the body than natural amylin and is thought to act on amylin receptors in the brain to increase feelings of fullness and slow stomach emptying. It is being developed mainly as a potential treatment for obesity and weight management.

What the evidence shows

Automatic summaryLimited human data

Petrelintide is not FDA-approved, and its human evidence comes from a small number of registered trials (9, with the most advanced listed as Phase 3) and about 6 published papers. Early studies have reported effects on body weight and tolerability, but its long-term effectiveness and safety in humans have not been established.

Key facts

Molecular formula

C185H305N49O61

Molecular weight

4192 g/mol

Registered human trials

Live from ClinicalTrials.gov, refreshed daily.

9registered studies

Phase 3most advanced phase

4completed (sample)

4recruiting (sample)

Investigating the Pharmacokinetics of Petrelintide Using Different Drug Product Concentrations

Phase 1CompletedNCT07338214

Pharmacokinetics of Petrelintide Following Administration to Participants With Impaired Renal Function

Phase 1CompletedNCT07076030

A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

Phase 2Not Yet RecruitingNCT07589686

A Phase III Study to Evaluate the Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity

Phase 3RecruitingNCT07843498

Published literature

Live from Europe PMC. This is how much has been published, not how much is proven in humans.

8papers referencing Petrelintide

Development of Petrelintide: a Potent, Stable, Long-Acting Human Amylin Analogue.

J Med Chem2025

Discovery of BGM1812, a Novel Dual Amylin and Calcitonin Receptor Agonist for Obesity Treatment.

J Med Chem2025

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Petrelintide for Weight Management: Two Randomized, Controlled Phase 1 Trials.

Diabetes Obes Metab2026

Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.

Peptides2026

Sources

Risks, side effects and study doses are only published on hand-reviewed profiles. Want this one reviewed, or spotted something wrong? Tell us.